Thus, treating patients prior to surgery with anti-PD1 antibody with or without 4-1BB agonism, followed by adjuvant CAR T cells with a third generation CD28/4-1BB-based CAR construct, could take advantage of the less “cold” tumour microenvironment to eliminate and control peripheral disease. The gene discussed is PDCD1; the disease is neoplasm.